Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Alongi

Showing results (291-300 of 305) with videos related to

Pageof 31
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 15, 2025
Re-irradiation in patients affected by prostate cancer and relapsing after previous definitive or postoperative radiotherapy. An international registry based study on behalf of Italian association of radiotherapy and clinical oncology (AIRO). (RE-START)Giulio Francolini, Vanessa Di Cataldo, Saverio Caini, et al.
Journal of Clinical Pathology|November 4, 2020
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinomaMatteo Brunelli, Alessandro Tafuri, Luca Cima, et al.
BMC Cancer|February 19, 2020
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
European Urology|July 24, 2019
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal RadiotherapyElise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al.
BMC Cancer|December 18, 2019
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
The Lancet. Oncology|March 1, 2023
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortiumStephanie G C Kroeze, Matea Pavic, Karin Stellamans, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 7, 2026
Biochemical control and 2-year tolerability following stereotactic body radiotherapy for localized prostate cancer: a multicenter study in SpainSigfredo Elias Romero Zoghbi, Fernando López Campos, Abrahams Ocanto, et al.
Cancer Treatment Reviews|May 9, 2021
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensusBarbara A Jereczek-Fossa, Giulia Marvaso, Mattia Zaffaroni, et al.
International Journal of Environmental Research and Public Health|January 20, 2021
The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients" Multi-Centre Observational StudyGiuseppe Deledda, Niccolò Riccardi, Stefania Gori, et al.
Radiology. Imaging Cancer|May 16, 2025
Impact of Metastasis-directed Therapy Guided by Different PET/CT Radiotracers on Distant and Local Disease Control in Oligorecurrent Hormone-sensitive Prostate Cancer: A Secondary Analysis of the PRECISE-MDT StudyFrancesco Lanfranchi, Liliana Belgioia, Domenico Albano, et al.
Pageof 31

Showing results (291-300 of 305) with videos related to

Sort By:
Pageof 31
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 15, 2025
Re-irradiation in patients affected by prostate cancer and relapsing after previous definitive or postoperative radiotherapy. An international registry based study on behalf of Italian association of radiotherapy and clinical oncology (AIRO). (RE-START)Giulio Francolini, Vanessa Di Cataldo, Saverio Caini, et al.
Journal of Clinical Pathology|November 4, 2020
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinomaMatteo Brunelli, Alessandro Tafuri, Luca Cima, et al.
BMC Cancer|February 19, 2020
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
European Urology|July 24, 2019
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal RadiotherapyElise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al.
BMC Cancer|December 18, 2019
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
The Lancet. Oncology|March 1, 2023
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortiumStephanie G C Kroeze, Matea Pavic, Karin Stellamans, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 7, 2026
Biochemical control and 2-year tolerability following stereotactic body radiotherapy for localized prostate cancer: a multicenter study in SpainSigfredo Elias Romero Zoghbi, Fernando López Campos, Abrahams Ocanto, et al.
Cancer Treatment Reviews|May 9, 2021
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensusBarbara A Jereczek-Fossa, Giulia Marvaso, Mattia Zaffaroni, et al.
International Journal of Environmental Research and Public Health|January 20, 2021
The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients" Multi-Centre Observational StudyGiuseppe Deledda, Niccolò Riccardi, Stefania Gori, et al.
Radiology. Imaging Cancer|May 16, 2025
Impact of Metastasis-directed Therapy Guided by Different PET/CT Radiotracers on Distant and Local Disease Control in Oligorecurrent Hormone-sensitive Prostate Cancer: A Secondary Analysis of the PRECISE-MDT StudyFrancesco Lanfranchi, Liliana Belgioia, Domenico Albano, et al.
Pageof 31